51 results about "Erythroid Progenitor Cells" patented technology

Provided are: a method for producing an immortalized human erythroid progenitor cell line, enabling efficient and stable production of enucleated red blood cells; and a method for producing human enucleated red blood cells from a human erythroid progenitor cell line obtained by the aforementioned production method. An expression cassette capable of inducing expression of HPV-E6 / E7 genes in the presence of DOX was introduced into the genomic DNA of blood stem cells. Then, the blood stem cells were cultured in the presence of DOX and a blood growth factor. Thereby, immortalized cell lines of human erythroid progenitor cells were established. Further, it was revealed that culturing the cell lines under a condition where the expression of the HPV-E6 / E7 genes was not induced enabled differentiation induction into enucleated red blood cells at a high ratio.

The invention discloses an erythroid progenitor cell cryopreservation liquid and application thereof, wherein the erythroid progenitor cell cryopreservation liquid comprises DMSO, HSA and plasma. The erythroid progenitor cell cryopreservation liquid is capable of effectively preserving erythroid progenitor cells for long preservation time; the multiplication capacity of cells after recovering is strong; the cell recovering rate is high.

The invention discloses traditional Chinese medicine composition for treating aplastic anemia and a preparation method, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared to form a formula according to the principle of the monarch, the minister, the assistant andthe guide; in the formula, astragalus, dried rehmannia roots, cooked rehmannia roots, glossy privet fruits and the like serve as the monarch; barbarywolfberry fruits, herbaepimedii, moutan bark, Chinese wolfberry root-bark, deerhorn glue and the like serve as the minister; herbaecliptae, ass hide glue, red paeony roots and the like serve as the assistant; and red dates, liquorice and the like serve as the guide; all the medicines are combined to achieve effects of curing livers, spleens and kidneys simultaneously and recovering functions of hematopoietic stem cells. The composition is mainly used for treating the aplastic anemia, can increase marrow hematopoietic cells, can remove hectic fever due to yin deficiency, can repair bones and add marrow, has an obvious promoting effect on generation of granulocytic erythrocytes and erythroid progenitor cells, can accelerate generation, differentiation and maturity of the hematopoietic cells, can improve the immune function, reduce damage to immune leukocytes, stimulate and activate the hematopoietic function, enables erythrocytes to generate blood vigorously, can promote generation of the erythrocytes and the leukocytes, can increase the number of blood platelets, can enhance functions of the blood platelets and the like.

The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions.

The invention belongs to the technical field of cells, and particularly relates to a method for improving directional differentiation effects on erythroid progenitor cells in umbilical cord blood.The method includes directionally differentiating and amplifying specimen cells by the aid of amplification cultivation media with piceatannol which is a natural compound.Hematopoietic stem cells in the umbilical cord blood are used as the specimen cells.The method has the advantages that directional differentiation operation on the erythroid progenitor cells can be easily, conveniently, safely and efficiently carried out by the aid of the amplification cultivation media with the piceatannol; the piceatannol and cytokines are simultaneously added into the hematopoietic stem cells in procedures for directionally differentiating and cultivating the hematopoietic stem cells to obtain the erythroid progenitor cells, accordingly, effects of increasing the quantities of the generated erythroid progenitor cells and improving BFU-E (burst forming unit-erythroid) colony formation ability can be realized, the method is easy and convenient to implement and low in cost, and the progenitor cells are high in safety and red blood cell differentiation capacity.

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte / erythroid progenitor cells (MEP) and granulocyte / monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid / megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize Thy-1; and IL-7Rα, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

The invention discloses erythroid progenitor cell cryopreservation liquid and application thereof, wherein the erythroid progenitor cell cryopreservation liquid comprises: DMSO; HSA; and blood plasma. The cryopreservation solution can effectively preserve the erythroid progenitor cells, and has a long storage time, and the cells have strong proliferation ability after thawing, and the cell recovery rate is high.

A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte / erythroid progenitor cells (MEP) and granulocyte / monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid / megakaryocytic or myelomonocytic lineages. Tηεχελλενιχημεντμετηoδσεμπλoψεαγεντστηατσπεχαλλψεψoγνιζε Tηψ-1; ανδIΛ-7 Pα, in conjunction with other markers expressed on lineage committed cells. These cells give rise to a variety of myeloid cells, including megakaryocytes, granulocytes, dendritic cells and erythroid cells, as evidenced by their growth and differentiation in vitro and in vivo.

The present invention discloses a compound for auxiliary anemia treatment and a preparation method thereof. The compound is composed of erythroid progenitor cells and MSC exosomes. Compared with traditional direct transfusion of red cells, in vivo differentiation of the erythroid progenitor cells is completer, use is convenient, increasingly lacking component blood resources are not occupied, andsocial medical burden is reduced; the MSC exosomes are used as substitutions of part of MSC functions, and MSC can be used for treating other severe diseases, so that the cost is considered, biological resources are utilized more comprehensively, and simplicity, convenience, safety and high efficiency are achieved; and long-acting red cell sources are provided for auxiliary anemia treatment by cooperation of the erythroid progenitor cells and the MSC exosomes, so that the compound has the relatively good effect for auxiliary anemia treatment. In addition, for lots of non-pathological anemia crowds, excessive medical treatment caused by direct transfusion of the red cells can be avoided, iron removing treatment and the like caused by repeated direct transfusion of the red cells is avoided,and the expense of a patient is reduced, so that the compound has the important medical prospect.

The invention involves biomedical field, concretely speaking, it involves the method and application of inducing hematopoietic stem / progenitor cells to erythroid differentiation of hematopoietic progenitor cells in vitro. This invention combines the genetic engineering and stem cell engineering, using the multipotency of stem cells and the bone marrow stromal cells of WNT3a in protein secretion activity as trophoblast cells, hematopoietic stem / progenitor cells to erythroid differentiation of hematopoietic progenitor cells is induced. this in vitro inducing system not only provides corroboration for the 'adult stem cell plasticity' theory, but also provides rich source of the cells as clinical preparation for diseases such as anemia, leukemia and other blood diseases, cancer chemotherapy and radiotherapy in the treatment of hematopoietic support, immune system diseases and infectious diseases such as liver and kidney dysfunction cell disease.

The invention discloses a cell bionic intelligent production system comprising a bioreactor, a medium container and an oxygen supply. The bioreactor comprises a sealed chamber formed by an outer casing and a plurality of hollow fiber tubes disposed in the chamber. The outer casing is provided with a medium inlet, a medium outlet and an oxygen inlet. The inner cavity of each hollow fiber tube is capable of circulating a basic medium and / or gas, the tail end of each hollow fiber tube is communicated with the basic medium container and / or the oxygen supply, the wall of each hollow fiber tube allows the composition of the basic medium and / or the gas to pass through the tube wall from the inner cavity side of the hollow fiber tube to the outside, and at least the outer surface of the tube wallof each hollow fiber tube is provided with a group suitable for cell denucleation. The medium container is provided with a supply port, and the supply port is connected to a medium inlet through a pipe. The oxygen supply is connected to an oxygen inlet through a pipe. The cell bionic intelligent production system is particularly suitable for cultivation of erythroid progenitor cells.

The present disclosure provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. Salmeterol or a pharmaceutically acceptable salt thereof may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. Also provided are methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of salmeterol or a pharmaceutically acceptable salt thereof. The present disclosure further provides methods comprising administering salbutamol or a pharmaceutically acceptable salt thereof. Salmeterol, salbutamol, or a pharmaceutically acceptable salt thereof may be administered conjointly with other FDA-approved drugs such as luspatercept, lenalidomide, daprodustat, vadadustat, an erythropoiesis-stimulating agent (ESA), and / or a hypomethylating agent.

The invention relates to a method for the in vitro production of erythroid progenitor cells, involving bringing hematopoietic stem cells, which may or may not be genetically modified, into contact with a defined cell culture medium that comprises a glucocorticoid hormone and an autophagy inducer.

It is an object of the present invention to provide a method for efficient differentiation into blood cells. Specifically, in the present invention, when blood cells are produced from pluripotent stem cells such as ES cells or iPS cells in vitro, the cells are cultured under a low oxygen partial pressure to increase the efficiency of differentiating the pluripotent stem cells into hematopoietic progenitor cells, erythroid progenitor cells, and the like, so as to increase the number of finally obtained, desired blood cells.

The invention provides application of GDF15 in preparation of a medicine for treating or preventing hematopoietic dysfunction caused by DON poisoning. The research finds that the GDF15 has the effects of treating or preventing bone marrow total cell reduction, hematopoietic stem progenitor cell damage, erythroid progenitor cell damage, erythroid end developmental stage damage, reticulocyte number reduction and peripheral blood mature erythrocyte damage caused by DON poisoning, and the exogenous GDF15 can relieve inhibition of DON poisoning on cell growth and development through research. And a GDF15-beta-catenin-Myc signal channel is activated, so that the downstream Myc, p27 and p21 are normally expressed. The invention discloses a new application of GDF15 in treatment of DON poisoning.

The invention discloses a lentiviral expression vector for inducing HPV16 E6 / E7 gene expression under hypoxia conditions. The lentiviral expression vector contains a hypoxia response element, a CMV-minimum promoter and a HPV16 E6 / E7 gene. The lentiviral expression vector can induce directional differentiation of hematopoietic stem cells into immortalized erythroid progenitor cells under the hypoxia conditions and the immortalized erythroid progenitor cells can differentiate into mature erythrocytes under normal oxygen supplying conditions. The erythrocytes induced by the vector has deformability and a oxygen bonding and release capability similar to those of the normal mature erythrocytes and has oxygen content of hemoglobin of 28+ / -2mmHg. The diameter of the erythrocyte injected into a mouse for 10min to 24h is decreased and the erythrocyte has a mature erythrocyte form in 24h and has good adaptability of existence in the body.

The purpose of the present invention is to provide an efficient differentiation method into blood cells. Specifically, according to the present invention, when blood cells are derived from pluripotent stem cells such as ES cells or iPS cells in vitro, the differentiation efficiency into blood progenitor cells, erythroid progenitor cells or the like is increased by carrying out the culture at a low oxygen partial pressure, thereby increasing the number of desired blood cells finally obtained.

Bone marrow erythroid progenitor cell(s) differentiation may be induced and anemia may be treated by administering arginine. Arginine is an excellent differentiation inducer, because it has high safety, can be orally administered, and is widely used.

The present invention relates to a method for differentiating canine hematopoietic stem cells into erythrocytes through in vitro culture, and a method for producing canine erythrocytes using same. According to the method, erythrocytes can be effectively produced from canine hematopoietic stem cells by using cytokines at specific concentrations.

The present disclosure relates to a SURF4 gene-knockout erythroid progenitor cell and a method of differentiating the same into an erythrocyte, wherein it has been determined that SURF4 gene-knockout cells, in which a SURF4 gene is knocked out in erythroid progenitor cells, express erythroid differentiation markers at a higher rate and undergo erythroid differentiation more rapidly under erythroid differentiation conditions according to the present disclosure, such that the present disclosure provides a method that enables rapid differentiation of erythrocytes using SURF4 gene-knockout erythroid progenitor cells.

It is an object of the present invention to provide a method for efficient differentiation into blood cells. Specifically, in the present invention, when blood cells are produced from pluripotent stem cells such as ES cells or iPS cells in vitro, the cells are cultured under a low oxygen partial pressure to increase the efficiency of differentiating the pluripotent stem cells into hematopoietic progenitor cells, erythroid progenitor cells, and the like, so as to increase the number of finally obtained, desired blood cells.

Provided are erythroid progenitor cell-derived extracellular vesicles comprising functional mitochondria, compositions comprising same, methods of making the mitochondriarich extracellular vesicles, and related therapeutic methods.

The invention discloses a lentiviral expression vector for inducing HPV16 E6 / E7 gene expression under hypoxia conditions. The lentiviral expression vector contains a hypoxia response element, a CMV-minimum promoter and a HPV16 E6 / E7 gene. The lentiviral expression vector can induce directional differentiation of hematopoietic stem cells into immortalized erythroid progenitor cells under the hypoxia conditions and the immortalized erythroid progenitor cells can differentiate into mature erythrocytes under normal oxygen supplying conditions. The erythrocytes induced by the vector has deformability and a oxygen bonding and release capability similar to those of the normal mature erythrocytes and has oxygen content of hemoglobin of 28+ / -2mmHg. The diameter of the erythrocyte injected into a mouse for 10min to 24h is decreased and the erythrocyte has a mature erythrocyte form in 24h and has good adaptability of existence in the body.

Disclosed in the present invention is a cell bionic intelligent production system, comprising a bioreactor, a medium container, and an oxygen supplier. The bioreactor comprises a sealed chamber formed by a housing and multiple hollow fiber tubes disposed in the chamber; the housing is provided with a medium inlet, a medium outlet, and an oxygen inlet; the inner cavity of the hollow fiber tube allows a basal medium and / or a gas to circulate, and the tail end of the hollow fiber tube can be communicated with a basal medium container and / or the oxygen supplier; the wall of the hollow fiber tube allows a component of the basal medium and / or a gas to pass from the inner cavity side of the hollow fiber tube to the outside through the wall; at least the outer surface of the wall of the hollow fiber tube is provided with a group suitable for cell denucleation. The medium container is provided with a supply port, and the supply port is connected to the medium inlet by means of a pipeline; the oxygen supplier is connected to the oxygen inlet by means of a pipeline. The cell bionic intelligent production system provided by the present invention is particularly suitable for cultivation of erythroid progenitor cells.

The present invention relates to SURF4 gene-deficient erythroid progenitor cells and a method for differentiating same into erythroid cells. SURF4 gene-deficient cells in which the SURF4 gene has been knocked out of erythroid progenitor cells were found to express erythroid differentiation markers at a higher proportion and undergo erythroid differentiation more rapidly under erythroid differentiation conditions according to the present invention. Accordingly, the present invention provides a method for rapidly differentiating erythrocytes using SURF4 gene-deficient erythroid progenitor cells.

The present invention relates to a medium composition for inducing erythroid differentiation and, more specifically, to: a medium composition for inducing erythroid differentiation; and a method for differentiating or producing erythrocytes, using same. It was confirmed that the medium composition for inducing erythroid differentiation, according to the present invention, can not only be prepared at very low costs as compared to conventional media, but can also rapidly induce the growth, differentiation, and enucleation of erythroid progenitor cells. Therefore, the medium composition for inducing erythroid differentiation, of the present invention, can be effectively used in blood-related clinical fields and therapeutic fields for diseases associated with reduced erythrocytes.

The invention belongs to the field of medicines, discloses an application of a CSF1R inhibitor in preparation of a medicine for treating or relieving myelofibrosis, and also discloses a medicine for treating or relieving myelofibrosis. According to the application disclosed by the invention, a delta (5q) MDS mouse model constructed based on Diaph1- / -miR-146a- / -(DKO) is treated by giving a CSF1R inhibitor PLX3397, and the following positive effects are observed: PLX3397 can relieve anemia symptoms of a DKO mouse, remarkably reduce the number of peripheral blood and fibrocytes in the spleen of the DKO mouse, reduce deposition of reticular fibers and collagenous fibers in bone marrow and effectively improve myelofibrosis. In addition, PLX3397 can also reduce the clone formation ability of peripheral blood and spleen of the DKO mouse and prolong the lifetime of the DKO mouse. Flow cytometry analysis shows that PLX3397 treatment can increase the number of early erythroid progenitor cells and LSK cells in bone marrow of a DKO mouse, so that hematopoietic function defects of the DKO mouse are partially improved. Generally speaking, the invention reveals the potential curative effect of PLX3397 in treating MDS mouse disease models, and provides a new direction for treating and relieving myelofibrosis caused by clinical treatment of MDS.

The application belongs to the technical field of biology, and discloses a kit for inducing stem cells to differentiate into megakaryocytes and / or platelets and application thereof. The kit can induce stem cells to differentiate into megakaryocytes and / or platelets without introducing exogenous cells and exogenous genes. The kit can highly simulate the generation process of megakaryocytes and platelets in vivo, and can induce stem cells into mesendoderm cells, hematopoietic endothelial cells and megakaryocyte-erythroid progenitor cells in sequence. The megakaryocyte-erythroid progenitor cells further develop into megakaryocytes with a multiploid characteristic, and finally produce stem cell-derived platelets with similar functions to natural platelets. The stem cells have the potential for unlimited proliferation, and can be massively expanded in vitro, which provides an unlimited cell source for the in vitro preparation of platelets.

The present invention relates to UT2 gene-deficient erythroid progenitor cells and a method for differentiating same into erythrocytes. It was confirmed UT2 gene-deficient cells in which the UT2 gene is knocked out in erythroid progenitor cells exhibit a higher expression ratio of erythroid differentiation markers and more rapid progression of erythroid differentiation under erythroid differentiation conditions according to the present invention, Accordingly, the present invention provides a method capable of rapidly differentiating erythroid cells using UT2 gene-deficient erythroid progenitor cells.

The invention relates to application of an active substance to improvement of erythroid progenitor cell differentiation efficiency, and belongs to the technical field of medicines. The active substance is selected from at least one of an Ataxin-2 inhibitor, an ATAD5 inhibitor, a histone-lysine N-methyltransferase inhibitor, a CREBBP inhibitor and a CBP ligand. Aiming at the problem of low efficiency of differentiation of hematopoietic stem / progenitor cells into erythrocytes in the conventional technology, screening is carried out by using massive compounds, adjustment and repeated screening are carried out according to a preliminary screening result, and after trial, a part of compounds are found to have the effect of improving the efficiency of differentiation of erythroid progenitor cells into erythroid cells; summary and conclusion are carried out according to the compounds, it is found that the target inhibitor has the effect of improving the efficiency of differentiating erythroid progenitor cells into erythroid cells, and the target inhibitor can be applied to the erythroid cell differentiation process to improve the differentiation efficiency.